Author Correction: Universal toxin-based selection for precise genome engineering in human cells.

التفاصيل البيبلوغرافية
العنوان: Author Correction: Universal toxin-based selection for precise genome engineering in human cells.
المؤلفون: Li S; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. songyuan.li@astrazeneca.com., Akrap N; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Cerboni S; Translational Science and Experimental Medicine, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Porritt MJ; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wimberger S; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Chemistry & Molecular Biology, University of Gothenburg, Gothenburg, Sweden., Lundin A; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Möller C; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Firth M; R&D Data Infrastructure & Tools, AstraZeneca, Cambridge, UK., Gordon E; Discovery Biology SWE, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Lazovic B; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland., Sieńska A; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Pane LS; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Coelho MA; Wellcome Sanger Institute, Cambridge, UK., Ciotta G; Discovery Biology UK, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Pellegrini G; CVRM pathology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sini M; CVRM pathology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Xu X; Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden., Mitra S; Inserm UMR1277 CNRS UMR9020 - CANTHER, Institut pour la Recherche sur le Cancer de Lille, Lille, France., Bohlooly-Y M; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Taylor BJM; Discovery Biology UK, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sienski G; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. grzegorz.sienski@astrazeneca.com., Maresca M; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Marcello.Maresca@astrazeneca.com.
المصدر: Nature communications [Nat Commun] 2021 May 10; Vol. 12 (1), pp. 2832. Date of Electronic Publication: 2021 May 10.
نوع المنشور: Published Erratum
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: PubMed not MEDLINE; MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
التعليقات: Erratum for: Nat Commun. 2021 Jan 21;12(1):497. (PMID: 33479216)
تواريخ الأحداث: Date Created: 20210511 Latest Revision: 20210514
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8110559
DOI: 10.1038/s41467-021-23345-z
PMID: 33972550
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-021-23345-z